{'fraction_non_alphanumeric': 0.042986425339366516, 'fraction_numerical': 0.04411764705882353, 'mean_word_length': 5.45985401459854, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

TAK‐701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c‐Met transduced signaling and c‐Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK‐701 based on immunochemical detection of HGF/c‐Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK‐701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK‐701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts. Pediatr Blood Cancer 2014;61:380–382. © 2013 Wiley Periodicals, Inc.